$7.63
-0.05 (-0.65%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CPIX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
47 interventional · 2 observational · 34 with posted results
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 2.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT05571059Change from baseline in Forced Vital Capacity (FVC) in mLRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Ifetroban Sodium, Placebo | Idiopathic Pulmonary Fibrosis | 128 | Jan 2027 | ≤ 165 d | 2026-03-05 |
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionNCT02682511Incidence of adverse events (AEs) and Serious AEs (SAEs)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Oral Ifetroban, Oral Placebo | Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases | 34 | Jun 2026 | — | 2026-04-15 |
| Oral Ifetroban in Subjects With Duchenne Muscular DystrophyNCT03340675results2026-01-26Incidence of Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ifetroban, Placebo | Duchenne Muscular Dystrophy Cardiomyopathy, Cardiomyopathy, Dilated | 46 | 2024-03-06actual | — | 2026-03-17 |
| Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)NCT03028350results2024-06-28Change From Baseline in Sinonasal Outcome Test-22 ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ifetroban Oral Capsule, Placebo Oral Capsule | Asthma, Aspirin-Induced | 54 | 2023-04-25actual | — | 2024-07-10 |
| Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)NCT02013141results2024-06-24Pharmacokinetics- Area Under the Curve Extrapolated to Infinity for the Plasma Concentration Versus Time Curves for TelavancinOpen-label · Basic scienceStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: FDA waived the pediatric study requirement for this application | Drug: Telavancin | Gram-Positive Bacterial Infections | 22 | Mar 2021actual | — | 2024-06-24 |
| VIBATIV Pregnancy RegistryNCT01130324observationalOutcomes of pregnancy in women exposed to VIBATIV at any time during pregnancy | — | Withdrawnsponsor's stated reason: Released by he FDA from this Post-Marketing Commitment | Drug: VIBATIV | Pregnancy | 0 | Oct 2020actual | — | 2020-10-19 |
| Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic PatientsNCT03611010results2022-07-15Efficacy, Number of Participants With Day 15 LDL-C Less Than or Equal to 125% of Baseline LDL-CNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Atorvastatin injection | Hypercholesterolemia, Dyslipidemias | 40 | 2020-02-17actual | — | 2022-07-15 |
| Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric PatientsNCT02583399results2020-11-20Area Under the Curve (AUC) 0-4 Hours of a Single Dose of Intravenous Ibuprofen (IVIb) Administered Over 5-7 Minutes.Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Ibuprofen | Pain, Fever | 30 | 2019-07-02actual | — | 2020-11-20 |
| Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic PatientsNCT02802228results2022-01-19Safety (Incidence and Severity of Adverse Events)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ifetroban, Placebo | Portal Hypertension, Liver Cirrhosis | 30 | 2018-07-17actual | — | 2022-01-19 |
| A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia TrialNCT02208063results2020-02-17Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Halted due to lack of statistical power. No safety concerns identified. | Drug: Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin | Bacteremia | 121 | 2018-04-12actual | — | 2020-02-17 |
| Telavancin Observational Use Registry (TOUR)NCT02288234observationalTime to clinical response | — | Completed | Drug: Vibativ | Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection | 1,063 | Jun 2017actual | — | 2019-01-15 |
| Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory DiseaseNCT02216357results2017-03-22Proportion of Patients Who Experience a ≥ 20% Decrease in Forced Expiratory Volume in One Second (FEV1) Compared to Baseline Following a Dose of Investigational Medicinal Product (IMP) (Study Day 1 or 2) Prior to Initiation of the Aspirin ChallengeRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Ifetroban, Oral Capsule, Placebo, Oral Capsule | Aspirin Exacerbated Respiratory Disease (AERD) | 19 | Jan 2016actual | — | 2017-05-15 |
| Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome PatientsNCT01436500results2017-02-14Half-life (T-1/2) of Ifetroban and Ifetroban AcylglucuronideRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Ifetroban Injection, Placebo | Hepatorenal Syndrome | 55 | Jun 2015actual | — | 2017-03-01 |
| Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee SurgeryNCT01901393results2016-02-15Efficacy of Pain Relief (Pain Intensity at Rest)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: IV ibuprofen, Ketorolac | Pain | 100 | Aug 2014actual | — | 2016-03-14 |
| Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for ColonoscopyNCT02123017results2016-02-24Efficacy of Bisacodyl and Lactulose as a Preparation for Colonoscopy.Non-randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: 90 grams of Crystalline Lactulose, 135 grams of Crystalline Lactulose, 180 grams of Crystalline Lactulose | Colonoscopy Preparation | 32 | Aug 2014actual | — | 2016-02-24 |
| A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous ConivaptanNCT01370148Assess the effect of severe hepatic impairment on the plasma drug concentration of conivaptan through analysis of blood samplesNon-randomized · Open-label | Phase 1 | Completed | Drug: conivaptan hydrochloride | Liver Disease | 17 | Feb 2014actual | — | 2014-05-02 |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic HyponatremiaNCT01451411results2016-03-01Mean Change From Baseline to the End of the 48-hour Treatment Period in Serum SodiumRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Enrollment goals were not met. | Drug: Conivaptan hydrochloride, Placebo | Hyponatremia | 4 | Jan 2014actual | — | 2016-03-01 |
| 2 Regimens of Lactulose for Colonoscopy Preparation in AdultsNCT01887470results2015-06-01Efficacy of Lactulose as a Preparation for Colonoscopy.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Full dose preparation, Split dose preparation | Colonoscopy Preparation | 55 | Oct 2013actual | — | 2015-06-01 |
| Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric PatientsNCT01002573results2016-11-07Fever ReductionRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: ibuprofen, acetaminophen | Fever | 118 | Jun 2013actual | — | 2016-11-07 |
| Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous IbuprofenNCT01334957results2014-06-23To Determine the Safety of a Single Dose of Intravenous Ibuprofen Over 5-10 Minutes for the Reduction of Pain.Open-label · Treatment | Phase 4 | Completed | Drug: Intravenous ibuprofen | Pain | 300 | Dec 2012actual | — | 2024-02-28 |
| A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee SurgeryNCT01650519results2014-07-10Efficacy of IV Ibuprofen for Post-op Pain.Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: IV ibuprofen, IV ketorolac | Arthroscopic Knee Surgery | 51 | Dec 2012actual | — | 2016-06-23 |
| Safety and Efficacy Study of a New Formulation of Acetylcysteine InjectionNCT01118663results2014-08-04The Incidence of Hepatoxicity as Measured by the Percentage of Subjects With an Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Value > 1000 U/L Versus Those With an ALT and AST < 1000 U/LRandomized · Quadruple-masked · Treatment | Phase 3 | Terminated | Drug: Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote | Acetaminophen Overdose | 17 | Nov 2012actual | — | 2014-08-04 |
| Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous IbuprofenNCT01334944results2014-06-23To Determine the Safety of a Single Dose of Intravenous Ibuprofen Administered Over 5-10 Minutes for the Treatment of Fever or Pain in the Hospital Setting.Open-label · Treatment | Phase 4 | Completed | Drug: Intravenous ibuprofen | Pain, Fever | 150 | Sep 2012actual | — | 2023-07-05 |
| Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing TonsillectomyNCT01332253results2016-11-03Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Intravenous ibuprofen · Other: Normal Saline | Tonsillectomy | 161 | Jul 2012actual | — | 2016-11-03 |
| A Study to Evaluate the Effect of Renal Function on the Biological Activity of TelavancinNCT01238796Concentration of telavancin as estimated by antibiotic potency bioassayNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: telavancin | Kidney Diseases, End Stage Renal Disease | 45 | Feb 2011actual | — | 2019-01-15 |
| Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney FunctionNCT00887627Measure PK and protein binding of conivaptanNon-randomized · Open-label | Phase 1 | Completed | Drug: conivaptan hydrochloride | Kidney Diseases, Hyponatremia | 25 | Jul 2010actual | — | 2014-05-02 |
| Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver FunctionNCT00851227Measure PK and protein binding of conivaptanNon-randomized · Open-label | Phase 1 | Completed | Drug: conivaptan hydrochloride | Liver Disease, Hyponatremia | 26 | Jan 2010actual | — | 2014-05-02 |
| A Preference Study Comparing Kristalose® and Liquid LactuloseNCT00712543results2011-09-27Patient Preference in Terms of Overall Preference and Preference of Taste, Consistency, and Portability.Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: lactulose (Kristalose®), liquid lactulose | Constipation | 50 | Sep 2009actual | — | 2011-09-27 |
| Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)NCT00843986results2010-10-01Change in Renal Function From Baseline at 72 Hours Assessed by Calculated Creatinine Clearance (MDRD Equation)Randomized · Triple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The clinical study has been terminated based on difficulties to enroll eligible subjects per protocol inclusion and exclusion criteria. | Drug: conivaptan, placebo | Hyponatremia, Acute Decompensated Heart Failure | 9 | Aug 2009actual | — | 2014-05-15 |
| Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn PatientsNCT00606489results2011-08-11TemperatureRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Caldolor, Placebo | Burns | 61 | May 2009actual | — | 2011-08-11 |
| Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult SubjectsNCT00867880To evaluate the pharmacokinetic profile of a single dose of IVIb administered over 5-7 minutes.Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: IVIb | Healthy | 12 | May 2009actual | — | 2014-12-15 |
| A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic PatientsNCT00592475results2010-09-28Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at 0.5, 1, and 1.5 Hours Post DoseRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: conivaptan, Placebo | Liver Cirrhosis | 20 | Nov 2008actual | — | 2014-05-15 |
| A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaNCT00435591results2010-05-26Number and Severity of Infusion Site Reactions (ISRs) Using a Modified ISR Reporting Scale for Phlebitis and Infiltration in Patients Treated With Dose Regimen 1 and Dose Regimen 2Randomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Conivaptan, placebo | Hyponatremia, Euvolemia, Hypervolemia | 121 | Sep 2008actual | — | 2014-05-15 |
| Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic PatientsNCT00470600results2011-12-08AUC-VAS With Movement (Post-operative Period, Hour-6-28)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Caldolor · Other: Normal Saline | Pain | 185 | Sep 2008actual | — | 2015-08-21 |
| Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaNCT00478192results2010-04-21Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Conivaptan, Placebo | Hyponatremia | 50 | Aug 2008actual | — | 2014-05-15 |
| Trial of Caldolor for Treatment of Pain in Post-Operative Adult PatientsNCT00225732results2011-09-15Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post SurgeryRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Other: Normal saline as placebo comparator · Drug: Intravenous ibuprofen | Pain | 319 | Jan 2008actual | — | 2016-06-22 |
| A Study of Caldolor in Hospitalized Febrile Pediatric PatientsNCT00225706TemperatureRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Caldolor | Fever | — | Aug 2007actual | — | 2010-04-12 |
| Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus AureusNCT00107952results2009-12-08Clinical ResponseRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Telavancin, Vancomycin | Bacterial Pneumonia | 761 | Jul 2007actual | — | 2019-01-16 |
| Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus AureusNCT00124020results2010-02-01Clinical ResponseRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Telavancin, Vancomycin | Bacterial Pneumonia | 771 | May 2007actual | — | 2019-01-16 |
| Telavancin for Treatment of Uncomplicated Staphylococcus Aureus BacteremiaNCT00062647results2011-03-22Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With Bacteremia, Metastatic Complications, or Positive Culture at the Test of Cure EvaluationRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin | Gram-Positive Bacterial Infections | 60 | Aug 2006actual | — | 2019-01-16 |
| Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus AureusNCT00091819results2009-12-08Clinical ResponseRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Telavancin, Vancomycin | Staphylococcal Skin Infection | 862 | Jun 2006actual | — | 2019-01-16 |
| Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus AureusNCT00107978results2010-02-01Clinical ResponseRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Telavancin, Vancomycin | Staphylococcal Skin Infection | 1,035 | May 2006actual | — | 2019-01-16 |
| Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile PatientsNCT01131000Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Ibuprofen, Ibuprofen, Ibuprofen · Other: Normal Saline | Fever | 123 | Aug 2005actual | — | 2010-05-26 |
| An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic HyponatremiaNCT00379847Baseline-adjusted change in AUC for serum sodiumRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: conivaptan | Hyponatremia | 251 | Jun 2005actual | — | 2014-05-02 |
| Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)NCT00077675results2010-01-11Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) PopulationRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Telavancin, vancomycin or antistaphylococcal penicillin | Infections, Gram-positive Bacterial | 201 | Sep 2004actual | — | 2019-01-16 |
| Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart FailureNCT00057356Change from baseline in respiratory Visual analog Scale (VAS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: conivaptan, placebo | Chronic Heart Failure | 170 | Mar 2004actual | — | 2014-05-02 |
| Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)NCT00061633results2010-01-11Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) PopulationRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Telavancin, Vancomycin or antistaphylococcal penicillin | Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections | 169 | Jan 2004actual | — | 2019-01-16 |
| Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic HyponatremiaNCT00380575The primary efficacy outcome will be change from baseline in serum sodium over the duration of treatment. The primary safety outcome will be safety parameters (e.g., adverse events, vital signs, EGG, laboratory measurements).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: YM087 | Hyponatremia | 84 | — | — | 2014-05-02 |
| Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic HyponatremiaNCT00492037Change in serum sodium from Baseline Safety of each dosing regimenRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: YM087 oral | Hyponatremia | 83 | — | — | 2014-05-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19